Recursion Pharmaceuticals harnesses AI for drug development, aiming for cost-effective and successful therapies. The company, publicly traded since 2021, faces challenges with a stock near its 52-week low. With clinical progress and collaborations, Recursion hopes to launch products and secure profits by 2030. However, competition and past failures pose risks to its success.

Read more at Yahoo Finance: Where Will Recursion Pharmaceuticals Be in 5 Years?